AAVhu68 Vector for Krabbe Disease CNS Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Krabbe disease, particularly hematopoietic stem cell transplant, have limited effectiveness in improving survival and motor outcomes for infantile patients and do not address peripheral neuropathy, highlighting the need for improved therapeutic options.

Innovation Solution

A recombinant adeno-associated virus (rAAV) vector is developed to target the central nervous system, encoding a galactosylceramidase protein with a specific amino acid sequence, packaged in an AAVhu68 capsid, and administered via intrathecal or intracerebroventricular routes to provide a disease-modifying treatment for Krabbe disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If hematopoietic stem cell transplant is used to treat Krabbe disease, then some therapeutic effect is achieved, but survival and motor outcomes for infantile patients remain limited and peripheral neuropathy is not addressed

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidsurvival improvement and motor outcome improvement

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The invention extracts the essential therapeutic function (GALC enzyme delivery) from the complex hematopoietic stem cell transplant procedure, using only the rAAV vector containing GALC coding sequence to achieve the core therapeutic effect without the limitations of cell transplant

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The rAAV vector serves as an intermediary carrier to deliver GALC enzyme directly to target cells, bypassing the need for hematopoietic stem cell engraftment and differentiation processes that limit current therapy effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If AAV9 capsid is used for CNS targeting, then gene delivery to central nervous system is achieved, but the need for additional variants to target different tissues indicates limited versatility

Engineering Contradiction:

ImproveCNS targeting efficiencyVSAvoidtissue targeting flexibility

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The AAVhu68 capsid provides universal CNS targeting capability that works effectively for delivering therapeutic genes to central nervous system tissues, while the modular vector design allows adaptation for other tissue targets through capsid variant selection

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20220118108A1Compositions useful in treatment of krabbe disease

Publication Date: 2022.04.21 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

A composition formulated for intrathecal delivery of a recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid carrying a human galactosylceramidase (GALC) gene for administration to Krabbe patients is provided. Also provided are novel gene sequences and uses thereof.